Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
· · OTC
$0.05
▼ $0.00 (-0.4%)
Market data updated: 09/16 10:26 PM
Fundamentals updated: 09/16/2026
News analyzed: 09/16/2026
Market Cap
$1.03M
Day Range
$0.04 - $0.04
52-Week Range
$0.04 - $0.10
Beta
—
Next Earnings
—
+1.8% (1Y)
Strengths: 5/16 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🔴 Bearish
Insiders
🟢 Bullish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Net income growth
Net income growth: 1304.8%
Growth
Biggest negative driver
Daily volatility (ATR)
ATR: 12.7% of price
Risk
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 1 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 1
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
47
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
58
Quality
No data available
Value
50
Momentum
28
Risk
42
Sentiment
50
Fundamental
60
Institutional
100
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of **CTT Pharmaceutical Holdings Inc.** highlights its strategic partnerships in the nicotine product sector. The company has signed **Letters of Intent (LOIs)** for clinical trials and testing collaborations, including one with a European firm, signaling expansion into research and development for nicotine-related products. These moves suggest a focus on advancing its clinical and regulatory efforts in this area.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about CTT Pharmaceutical Holdings Inc.. News trend score: 50. Reason: The mix of positive and negative articles is balanced — 0 vs. 0 out of the last 2 articles.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
14
🎯 Conviction (vs. Emotion)
50
Psychology
78
Fundamentals
60
Technical
28
Valuation
50
A significant decline over time, but on unusually low trading volume — holders unwilling to accept the loss.
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-40%
Market Narrative
40
Fundamental Reality
50
Narrative Gap
-10
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior for CTTH strongly suggests **loss aversion** is the dominant psychological state, driven by a pronounced 3-month decline (-37.8%) and muted trading activity (0.55x average volume). This aligns with investors clinging to positions to avoid realizing further losses, despite modest volatility (1.10x ATR) and neutral technical indicators. The narrative gap (-17) hints at a disconnect where sentiment (33) lags reality (50), reinforcing caution. The key open question: *Will the stock’s proximity to support (17.3% away) trigger defensive holding, or will declining momentum (-11.9% ROC) force liquidation?*
Updated: 09/09/2026, 02:57 PM
What could change this?
👥 What the crowd believes
"CTT Pharma signs LOI for clinical trials and testing"
📈 10D Investor Psychology
Signal classification confidence: Medium (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Charles Mackay — 100/100
🔴 Weakest match
Morgan Housel — 0/100
🗣️ Why do they disagree?
This stock’s starkly divided verdicts reflect a clash between cyclical, trend-following, and fundamental approaches. The highest-scoring methodologies—Mackay, Marks (Market Cycle), and Veblen—see it as a low-risk, value-aligned opportunity, with Mackay noting no crowd mania and Marks confirming it’s early-to-mid cycle. Meanwhile, Nelson and Schwager also endorse it as a disciplined, reward-rich setup, though with slightly more caution. However, the sharp contrast emerges when comparing these to the lowest scorers: Livermore and Loeb flag it as a trend *against* their rules, while Housel’s zero score suggests it’s volatile enough to deter patient, long-term holders. The middle tier—Graham, Fisher, and Lynch—all fail due to insufficient data, highlighting a lack of clear fundamentals or valuation anchors, while the efficient-market camp dismisses it outright as a suboptimal bet. The debate thus hinges on whether the stock’s cyclical positioning or volatility outweighs its structural appeal.
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 100
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟢 87
Growth appears aligned with real value creation
Key question
Is management building real value, or just building itself?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟢 78
A real, disciplined setup with favorable reward/risk
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 76
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 73
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟡 50
Not enough balance-sheet/valuation data for a real Graham read
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 50
Not enough fundamentals data for a real Fisher read
Key question
How exceptional is this business, really?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Peter Lynch
One Up on Wall Street (1989)
🟡 50
Not enough growth data for a real Lynch read
Key question
Is the growth worth the price?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Walter Bagehot
Lombard Street (1873)
🟡 50
Not enough balance-sheet data for a real Bagehot read
Key question
Does this company have enough liquidity to survive real stress?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟡 50
Not enough valuation data for a real Enterprising-Graham read
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 0%
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 40
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 37
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🔴 26
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 15
Not enough dividend/growth data for a real Smith read
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
⚠️ Partial data for this stock — score is less reliable — Data availability: 25%
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🔴 0
The kind of volatility that tends to shake patient holders out
Key question
Could I live with this volatility long enough for compounding to actually work?
⚠️ Partial data for this stock — score is less reliable — Data availability: 30%
Fact → Principle → Simulation
Based on the last 266 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (2 bullish · 8 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear downtrend with no defined trading range in the period examined.
Low confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
—
Net Margin
—
EBITDA Margin
—
ROE
38.8%
ROA
13.7%
ROIC
—
EPS
—
Cash
$81.18K
Total Debt
—
Current Ratio
—
Debt/Equity
—
אין נתונים היסטוריים זמינים.
אין נתונים היסטוריים זמינים.
How is Fair Value calculated? →
Not enough cash-flow data to calculate a DCF model for this stock.
Book Value per Share
—
Tangible Book Value per Share (Tangible NAV)
—
Not enough data to compute signals.
Sentiment based on basic keywords (not AI) — 0 positive, 2 neutral, 0 negative out of the last 2 articles.
ACCESS Newswire · 22.6.2026
ACCESS Newswire · 17.6.2026
CTT Pharmaceutical Holdings Inc. (CTTH) currently has a StockIQ AI score of 47/100, rated "Moderate" (a partial score — based on only 6 of 7 categories, some data is currently unavailable). The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
CTTH currently scores 47/100 (Moderate) across the categories we measure (a partial score — based on only 6 of 7 categories, some data is currently unavailable). StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
CTTH's technical score is 28/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Net income growth: 1304.8%; Return on equity (ROE): 38.8% — strong; MACD histogram is positive — rising momentum.
Based on the real signals StockIQ computed: ATR: 12.7% of price; Price is below the 50-day average; Price is below the 200-day average.
StockIQ has no recorded dividend payment history for CTTH.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 21 purchases and 0 sales out of the last 22 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 10.9.2026 | 3,500 | +3,500 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 4.9.2026 | 9,800 | +9,800 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 2.9.2026 | 3,000 | +3,000 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 31.8.2026 | 9,384,256 | +3,500 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 31.8.2026 | 3,500 | +3,500 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 24.8.2026 | 9,360,756 | +2,100 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 24.8.2026 | 2,100 | +2,100 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 20.8.2026 | 11,500 | +11,500 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 19.8.2026 | 10,000 | +10,000 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 14.8.2026 | 1,800 | +1,800 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 7.8.2026 | 7,700 | +7,700 | $0.07 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 17.12.2025 | 8,300 | +8,300 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 20.11.2025 | 200,000 | +200,000 | $0.04 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 20.11.2025 | 62,900 | +62,900 | $0.04 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 31.10.2025 | 7,000 | +7,000 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 23.9.2025 | 6,815 | +6,815 | $0.06 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 2.8.2025 | 44,085 | +44,085 | $0.05 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Grant/Award from Employer | 1.8.2025 | 750,000 | +750,000 | $0.04 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 1.8.2025 | 15,800 | +15,800 | $0.04 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 8.7.2025 | 8,000 | +8,000 | $0.03 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 26.6.2025 | 39,600 | +39,600 | $0.03 |
| CTT PHARMACEUTICAL HOLDINGS, INC. | Open Market Purchase | 23.6.2025 | 16,100 | +16,100 | $0.03 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,050 shares short as of 2026-08-31 · vs. 19,700 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
88.9% of trading volume this week was short selling, vs. 80.6% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology